Drug
Ak111
Ak111: highest development phase Phase 3, developed by Akeso. 2 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Akeso
Trials
| Drug | Phase | Indication |
|---|---|---|
| AK111 NCT06378697 | Phase 3 | Ankylosing Spondylitis |
| AK111 NCT05504317 | Phase 1 | Psoriasis |
Latest
No recent events.
Follow Ak111 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.